Breaking tolerance with engineered class I antigen-presenting molecules

Christopher A. Parks, Kalli R. Henning, Kevin D. Pavelko, Michael J. Hansen, Virginia P. Van Keulen, Brendan K. Reed, Jennifer D. Stone, Adam G. Schrum, Diana Gil, David M. Kranz, Andrew J. Bordner, Michael A. Barry, Larry R. Pease

Research output: Contribution to journalArticle

Abstract

Successful efforts to activate T cells capable of recognizing weak cancer-associated self-antigens have employed altered peptide antigens to activate T cell responses capable of cross-reacting on native tumor-associated self. A limitation of this approach is the requirement for detailed knowledge about the altered self-peptide ligands used in these vaccines. In the current study we considered allorecognition as an approach for activating CTL capable of recognizing weak or self-antigens in the context of self-MHC. Nonself antigen-presenting molecules typically contain polymorphisms that influence interactions with the bound peptide and TCR interface. Recognition of these nonself structures results in peptide-dependent alloimmunity. Alloreactive T cells target their inducing alloantigens as well as third-party alloantigens but generally fail to target self-antigens. Certain residues located on the alpha-1/2 domains of class I antigen-presenting molecules primarily interface with TCR. These residues are more conserved within and across species than are residues that determine peptide antigen binding properties. Class I variants designed with amino acid substitutions at key positions within the conserved helical structures are shown to provide strong activating signals to alloreactive CD8 T cells while avoiding changes in naturally bound peptide ligands. Importantly, CTL activated in this manner can break self-tolerance by reacting to self-peptides presented by native MHC. The ability to activate self-tolerant T cells capable of cross-reacting on self-peptide-MHC in vivo represents an approach for inducing autoimmunity, with possible application in cancer vaccines.

Original languageEnglish (US)
Pages (from-to)3136-3145
Number of pages10
JournalProceedings of the National Academy of Sciences of the United States of America
Volume116
Issue number8
DOIs
StatePublished - Feb 19 2019

Fingerprint

Histocompatibility Antigens Class I
Peptides
T-Lymphocytes
Autoantigens
Isoantigens
Antigens
Ligands
Self Tolerance
Cancer Vaccines
Amino Acid Substitution
Autoimmunity
Neoplasms
Vaccines

Keywords

  • Adenovirus
  • Cancer immunotherapy
  • MHC
  • T cells
  • Tolerance

ASJC Scopus subject areas

  • General

Cite this

Parks, C. A., Henning, K. R., Pavelko, K. D., Hansen, M. J., Van Keulen, V. P., Reed, B. K., ... Pease, L. R. (2019). Breaking tolerance with engineered class I antigen-presenting molecules. Proceedings of the National Academy of Sciences of the United States of America, 116(8), 3136-3145. https://doi.org/10.1073/pnas.1807465116

Breaking tolerance with engineered class I antigen-presenting molecules. / Parks, Christopher A.; Henning, Kalli R.; Pavelko, Kevin D.; Hansen, Michael J.; Van Keulen, Virginia P.; Reed, Brendan K.; Stone, Jennifer D.; Schrum, Adam G.; Gil, Diana; Kranz, David M.; Bordner, Andrew J.; Barry, Michael A.; Pease, Larry R.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 116, No. 8, 19.02.2019, p. 3136-3145.

Research output: Contribution to journalArticle

Parks, CA, Henning, KR, Pavelko, KD, Hansen, MJ, Van Keulen, VP, Reed, BK, Stone, JD, Schrum, AG, Gil, D, Kranz, DM, Bordner, AJ, Barry, MA & Pease, LR 2019, 'Breaking tolerance with engineered class I antigen-presenting molecules', Proceedings of the National Academy of Sciences of the United States of America, vol. 116, no. 8, pp. 3136-3145. https://doi.org/10.1073/pnas.1807465116
Parks, Christopher A. ; Henning, Kalli R. ; Pavelko, Kevin D. ; Hansen, Michael J. ; Van Keulen, Virginia P. ; Reed, Brendan K. ; Stone, Jennifer D. ; Schrum, Adam G. ; Gil, Diana ; Kranz, David M. ; Bordner, Andrew J. ; Barry, Michael A. ; Pease, Larry R. / Breaking tolerance with engineered class I antigen-presenting molecules. In: Proceedings of the National Academy of Sciences of the United States of America. 2019 ; Vol. 116, No. 8. pp. 3136-3145.
@article{6a6e6caa9a6d4701a6e4ef5ef4e9abb9,
title = "Breaking tolerance with engineered class I antigen-presenting molecules",
abstract = "Successful efforts to activate T cells capable of recognizing weak cancer-associated self-antigens have employed altered peptide antigens to activate T cell responses capable of cross-reacting on native tumor-associated self. A limitation of this approach is the requirement for detailed knowledge about the altered self-peptide ligands used in these vaccines. In the current study we considered allorecognition as an approach for activating CTL capable of recognizing weak or self-antigens in the context of self-MHC. Nonself antigen-presenting molecules typically contain polymorphisms that influence interactions with the bound peptide and TCR interface. Recognition of these nonself structures results in peptide-dependent alloimmunity. Alloreactive T cells target their inducing alloantigens as well as third-party alloantigens but generally fail to target self-antigens. Certain residues located on the alpha-1/2 domains of class I antigen-presenting molecules primarily interface with TCR. These residues are more conserved within and across species than are residues that determine peptide antigen binding properties. Class I variants designed with amino acid substitutions at key positions within the conserved helical structures are shown to provide strong activating signals to alloreactive CD8 T cells while avoiding changes in naturally bound peptide ligands. Importantly, CTL activated in this manner can break self-tolerance by reacting to self-peptides presented by native MHC. The ability to activate self-tolerant T cells capable of cross-reacting on self-peptide-MHC in vivo represents an approach for inducing autoimmunity, with possible application in cancer vaccines.",
keywords = "Adenovirus, Cancer immunotherapy, MHC, T cells, Tolerance",
author = "Parks, {Christopher A.} and Henning, {Kalli R.} and Pavelko, {Kevin D.} and Hansen, {Michael J.} and {Van Keulen}, {Virginia P.} and Reed, {Brendan K.} and Stone, {Jennifer D.} and Schrum, {Adam G.} and Diana Gil and Kranz, {David M.} and Bordner, {Andrew J.} and Barry, {Michael A.} and Pease, {Larry R.}",
year = "2019",
month = "2",
day = "19",
doi = "10.1073/pnas.1807465116",
language = "English (US)",
volume = "116",
pages = "3136--3145",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "8",

}

TY - JOUR

T1 - Breaking tolerance with engineered class I antigen-presenting molecules

AU - Parks, Christopher A.

AU - Henning, Kalli R.

AU - Pavelko, Kevin D.

AU - Hansen, Michael J.

AU - Van Keulen, Virginia P.

AU - Reed, Brendan K.

AU - Stone, Jennifer D.

AU - Schrum, Adam G.

AU - Gil, Diana

AU - Kranz, David M.

AU - Bordner, Andrew J.

AU - Barry, Michael A.

AU - Pease, Larry R.

PY - 2019/2/19

Y1 - 2019/2/19

N2 - Successful efforts to activate T cells capable of recognizing weak cancer-associated self-antigens have employed altered peptide antigens to activate T cell responses capable of cross-reacting on native tumor-associated self. A limitation of this approach is the requirement for detailed knowledge about the altered self-peptide ligands used in these vaccines. In the current study we considered allorecognition as an approach for activating CTL capable of recognizing weak or self-antigens in the context of self-MHC. Nonself antigen-presenting molecules typically contain polymorphisms that influence interactions with the bound peptide and TCR interface. Recognition of these nonself structures results in peptide-dependent alloimmunity. Alloreactive T cells target their inducing alloantigens as well as third-party alloantigens but generally fail to target self-antigens. Certain residues located on the alpha-1/2 domains of class I antigen-presenting molecules primarily interface with TCR. These residues are more conserved within and across species than are residues that determine peptide antigen binding properties. Class I variants designed with amino acid substitutions at key positions within the conserved helical structures are shown to provide strong activating signals to alloreactive CD8 T cells while avoiding changes in naturally bound peptide ligands. Importantly, CTL activated in this manner can break self-tolerance by reacting to self-peptides presented by native MHC. The ability to activate self-tolerant T cells capable of cross-reacting on self-peptide-MHC in vivo represents an approach for inducing autoimmunity, with possible application in cancer vaccines.

AB - Successful efforts to activate T cells capable of recognizing weak cancer-associated self-antigens have employed altered peptide antigens to activate T cell responses capable of cross-reacting on native tumor-associated self. A limitation of this approach is the requirement for detailed knowledge about the altered self-peptide ligands used in these vaccines. In the current study we considered allorecognition as an approach for activating CTL capable of recognizing weak or self-antigens in the context of self-MHC. Nonself antigen-presenting molecules typically contain polymorphisms that influence interactions with the bound peptide and TCR interface. Recognition of these nonself structures results in peptide-dependent alloimmunity. Alloreactive T cells target their inducing alloantigens as well as third-party alloantigens but generally fail to target self-antigens. Certain residues located on the alpha-1/2 domains of class I antigen-presenting molecules primarily interface with TCR. These residues are more conserved within and across species than are residues that determine peptide antigen binding properties. Class I variants designed with amino acid substitutions at key positions within the conserved helical structures are shown to provide strong activating signals to alloreactive CD8 T cells while avoiding changes in naturally bound peptide ligands. Importantly, CTL activated in this manner can break self-tolerance by reacting to self-peptides presented by native MHC. The ability to activate self-tolerant T cells capable of cross-reacting on self-peptide-MHC in vivo represents an approach for inducing autoimmunity, with possible application in cancer vaccines.

KW - Adenovirus

KW - Cancer immunotherapy

KW - MHC

KW - T cells

KW - Tolerance

UR - http://www.scopus.com/inward/record.url?scp=85061864613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061864613&partnerID=8YFLogxK

U2 - 10.1073/pnas.1807465116

DO - 10.1073/pnas.1807465116

M3 - Article

C2 - 30728302

AN - SCOPUS:85061864613

VL - 116

SP - 3136

EP - 3145

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 8

ER -